BioMarin Pharmaceutical has completed its acquisition of Amicus Therapeutics, buying the company for $14.50 per share in an all-cash deal.

AstraZeneca has received approval from the FDA for the subcutaneous self-administration of Saphnelo using the Saphnelo pen for SLE.

Ajax’s lead asset is AJ1-11095, a once-daily Type II JAK2 inhibitor taken orally, which is currently in a Phase I trial.

AI capabilities within pharma are evolving from add-on to an arm of core business demanding overhauled AI governance.

Bowel cancer, also known as colorectal cancer, is the second most lethal cancer after lung cancer, with the highest incidence rates being reported in developed countries. Accordin ...

Pharmaceutical trade associations across the Nordic region have reacted with vigilance to a recent GlobalData report that highlighted the potential effect on product launch and withdrawal trends in ...

AI tools that slash time spent on administration prove their worth and free up pharma workers for higher value tasks.

Novartis has secured a pair of regulatory wins from the European Commission and World Health Organization. Credit: OleksSH/Shutterstock.com. Novartis has netted a pair of regulatory wins, winning ...

Sun Pharma has signed a definitive agreement to acquire Organon in a transaction with an enterprise valuation of $11.75bn in cash.

With an uptick and increasingly even spread of capital across the space, the BIA’s Martin Turner is optimistic for British biotech’s future.

This White House deal will see Regeneron offer all its new medicines at “MFN prices”, while providing Otarmeni for free to eligible patients.

The EMA’s CHMP has stated its positive opinions on three drugs for autoimmune, muscle wasting and rare genetic diseases.